中国媒介生物学及控制杂志

• 分题报告 • 上一篇    下一篇

浙江省肾综合征出血热纯化灭活疫苗的免疫效果和免疫策略研究

夏建华1; 翁景清1; 赵芝雅1; 龚震宇1; 朱智勇1; 兰锦清2; 陈毓土2; 徐江荣2; 季群伟2; 张庆梅2; 陈晓峰2; 吴云高2; 来庆华2; 林正渠2; 余新顺3; 方春福3; 王玮3; 吕跃民3; 龚晓兰3; 廖水法4; 范小钢4; 汤樟全4   

  1. 1浙江省卫生防疫站; 2龙游县卫生防疫站; 3龙游县卫; 4龙游溪口区卫生院
  • 出版日期:1997-10-20 发布日期:1997-10-20

Study on the Immunological Effect and Strategy of Purified Inactivated Vaccine against HFRS in Zhejiang Province

Xia Jian-hua; Wong Jing-qing; Zhao Zhi-ya; et al   

  1. Zhejiang Provincial Health and Anti-Epidemic Station
  • Online:1997-10-20 Published:1997-10-20

摘要: 目的:观察HFRS(Ⅰ型)鼠脑纯化灭活疫苗全程和加强免疫后18个月的流行病学。血清学效果。方法:采用免疫荧光法检测微量细胞病变试验,分别检测血清中的特异性抗体及中和抗体。结果:全程免疫后15天,中和抗体阳性率为40%,GMT为4.06;360天降为阴性,GMT为2.50;加强后2周抗体阳性率为50%,GMT为4.35.全程免疫后15天IFA抗体阳性率为100%,GMT为81.75;至360天阳性率降至12.50%,GMT为5.69;加强后2周阳性率升至81.25%,GMT为1297。加强免疫6363例,仅2例出现弱反应,无中、强反应。免后18个月经流行病学调查,1年内(经春、秋两个流行高峰)接种组发病2例,发病率为19.12/10万;对照组发病12例,发病率为74.06/10万,保护率为74.18%,保护指数为3.87;加强1针后的6个月中,接种组无病例,对照组发病3例,发病率47.15/10万,保护率达100%。结论:该疫苗安全性好;有较好的免疫应答;近期和中期流行病学防病效果良好。

关键词: 肾综合征出血热, 乳鼠脑Ⅰ型, 纯化灭活疫苗, 加强免疫, 防病效果

Abstract: Obective: The purpee of this report was to observe the epidemiological and seroogical effect of type Ⅰpurified inactivated vaccine against HFRS (prepared from mouse brains) in the whole course of immunization and 18 monthes after reinforced.Methods: Immunofluorescent antibody assay and micrcrCPE neutralization test were used in testing SPecific IgG antibody and neutralizing antibody, respectively.Results: 15 days, 360 days after the whole course of immunization and 2 weeks after reinforced.The positive rates of neutralizing antibody were 40%, 0%, 50% and GMT were 4.06, 2.50, 4.35, respectively; the Positive rate of IFA antibody were 100%, 12.50%, 81.25%, and GMT were 81.75, 5.69,12.97 respectively.Weak responses were found in 2 among 6363 cases of reinforced immunization.No medium and strong response was found.18 monthes after immunization, the epidendological survey showed that during 1 year (with two epidemic peak in spring and autumn) there were 2 patientS in the inoculation group, the mobidity was 19.12/100, 000, and 12 patients in the control group, the mobidity was 74.06/100, 000, the protection rate was 74.18%, the protection index was 3.87.In 6 monthes after reinforced, there was no patient in the in oculation group and 3 cases in the control group, the mobidity rate was 47.15/100, 000, the protection rate was 100%.Chnclusion: The vaccine was safe and immunologically effective.